Biomarin Pharmaceutical (BMRN) Gains from Investment Securities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$5.0 million for Q1 2026.

• Quarterly Gains from Investment Securities changed N/A year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.6 million (up 353.24% YoY) and the FY2025 annual result came in at $38.6 million, up 3480.63% from the prior year.
• Gains from Investment Securities rose to -$5.0 million in Q1 2026, from -$14.7 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $70.8 million in Q3 2023 and troughed at -$14.7 million in Q4 2025.
• A 5-year average of $6.9 million and a median of $869500.0 in 2022 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities tumbled 897.74% — and 2025, when it surged 12866.92%.
• Tracing BMRN's Gains from Investment Securities over 5 years: stood at $1.3 million in 2022, then jumped by 191.88% to $3.9 million in 2023, then tumbled by 161.1% to -$2.4 million in 2024, then sank by 513.44% to -$14.7 million in 2025, then soared by 66.2% to -$5.0 million in 2026.
• Business Quant data shows BMRN's Gains from Investment Securities at -$5.0 million in Q1 2026, -$14.7 million in Q4 2025, and $51.3 million in Q3 2025.